Alk-abello A/s Class B · OMXCOP:ALK_B

Alk-abello A/s Class B — Alk-Abello As B Shs New — Q3 2024 Earnings Presentation

11 slides from Alk-abello A/s Class B's earnings presentation, Nov 14, 2024

  1. Slide 1: Q3 2024 presentation

    Q3 2024 presentation Webcast 14 November 2024

  2. Slide 2: Agenda and presenters

    2 Webcast 14 November 2024 Agenda and presenters • Q3 highlights • Performance o Market trends o Product sales trends o 9M financials • Strategy President & CEO EVP, Group CFO VP, Head of IR o Allergy+ highlights Peter Halling Claus Steensen Sølje Per Plotnikof o Anaphylaxis • 2024 outlook This pres

  3. Slide 3: Q3 highlights

    3 Webcast 14 November 2024 Q3 highlights Unchanged full-year financial outlook • Broad-based growth across geographies and product lines • Continued momentum in EU tablet sales; rebound in Jext® sales • 23% EBIT margin in line with financial targets • Strategy progresses, particularly in Anaphylaxis

  4. Slide 4: EU and Int'l markets key contributors to growth

    4 Webcast 14 November 2024 EU and Int’l markets key contributors to growth Europe North America International markets 67% 17% 16% Double-digit growth across Northern SCIT bulk sales sustained 39% growth in tablet revenue; and Central EU markets, driven by the trend from Q2-24; disappointing higher S

  5. Slide 5: Tablet and Jext sales grow by double-digits

    5 Webcast 14 November 2024 Tablet and Jext® sales grow by double-digits Tablets SCIT/SLIT-drops Other products 48% 39% 13% Double-digit growth in all regions; Single-digit growth in all regions; Jext® sales recovered EU sales up 27% on the past year’s 5% growth in EU impacted by tough with triple-di

  6. Slide 6: Topline growth drives margin improvements

    6 Webcast 14 November 2024 Topline growth drives margin improvements DKK 49 million one-off costs included in 9M EBIT result DKK million 9M 2024 9M 2023 Change Gross profit DKKm % Revenue 4,038 3,479 +16% 900 68 720 66 Gross profit 2,598 2,191 540 64 360 Gross margin 64.3% 63.0% 180 62 0 60 Capacity

  7. Slide 7: Strategy highlights

    7 Webcast 14 November 2024 Strategy highlights Implementation progresses • In-licensing of neffy® to support ambitions in anaphylaxis and new TAs • Phase I/II trial in peanut allergy set to report results late Q4 ≥10% revenue growth 2023-28 (CAGR) • Ongoing processes to secure approvals of tablets f

  8. Slide 8: ALK acquires exclusive rights to neffy

    8 Webcast 14 November 2024 ALK acquires exclusive rights to neffy® First and only FDA- and EMA-approved adrenaline nasal spray for severe allergic reactions (anaphylaxis) Respiratory Allergy neffy® deal supportive of ALK’s growth ambitions ALK core business with sustained growth potential • ALK gain

  9. Slide 9: Full-year outlook is unchanged

    9 Webcast 14 November 2024 Full-year outlook is unchanged Revenue Key assumptions • Robust, double-digit growth in EU DKKm % 14-16% • Single-digit growth in NAM and Int’l markets 6,000 4,500 20 15 Growth in • Growth in EU tablet sales to significantly rebound 3,000 10 local currencies • Mid to high

  10. Slide 10: Q&A session

    Q&A session

  11. Slide 11: Upcoming news and events

    11 Webcast 14 November 2024 Upcoming news and events 15 Nov 2024 Q3 roadshow, Copenhagen 19 Nov 2024 Q3 roadshow, Paris 20 Nov 2024 Q3 roadshow, London 26 Nov 2024 DNB Health Care Seminar, Oslo 27 Nov 2024 Danske Bank Copenhagen Winter Seminar 07 Jan 2025 SEB Nordic Seminar, Copenhagen 9-10 Jan 2025

Alk-Abello As B Shs New — Q3 2024 Earnings Presentation on 6ix